Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy

• Verfasst von: Möhler, Thomas [VerfasserIn]
• Verfasst von: Neben, Kai [VerfasserIn]
• Verfasst von: Benner, Axel [VerfasserIn]
• Verfasst von: Egerer, Gerlinde [VerfasserIn]
• Verfasst von: Krasniqi, Fatime [VerfasserIn]
• Verfasst von: Ho, Anthony Dick [VerfasserIn]
• Verfasst von: Goldschmidt, Hartmut [VerfasserIn]
• Titel: Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy
• Verf.angabe: Thomas M. Moehler, Kai Neben, Axel Benner, Gerlinde Egerer, Fatime Krasniqi, Anthony D. Ho, and Hartmut Goldschmidt
• E-Jahr: 2001
• Jahr: [December 15, 2001]
• Umfang: 3 S.
• Illustrationen: Diagramme
• Fussnoten: Gesehen am 01.03.2022
• Titel Quelle: Enthalten in: Blood
• Ort Quelle: Washington, DC : American Society of Hematology, 1946
• Jahr Quelle: 2001
• Band/Heft Quelle: 98(2001), 13 vom: Dez., Seite 3846-3848
• ISSN Quelle: 1528-0020
• DOI: doi:10.1182/blood.V98.13.3846
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1794145176

Abstract

The feasibility and efficacy of a combination of thalidomide, cyclophosphamide, etoposide, and dexamethasone were studied in 56 patients with poor-prognosis multiple myeloma. Of 50 patients evaluable for response, 4% achieved complete response (CR), 64% partial response (PR), 18% minimal response (MR), 6% stable disease (SD), and 8% progressive disease (PD), resulting in an objective response rate (≥ MR) of 86.0% (76.7% overall objective response rate in intent-to-treat analysis; n = 56). Subsequent to successful remission induction, 18 patients received autologous or allogeneic stem cell transplantation. The median progression-free survival in all patients was 16 months. The median overall survival time could not be calculated, since the last observed death occurred after 16 months of follow-up (median follow-up of 14 months) with a corresponding estimated survival probability of 55%. Severe adverse effects (World Health Organization III/IV) included infectious complications (35.7%) and cardiovascular events (7.1%). The data suggest that Thal improves antitumor activity of salvage chemotherapy regimens in poor-prognosis multiple myeloma.